Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study

  • Garrick D. Talmage,
  • Oscar J. M. Coppes,
  • Adil Javed,
  • Jacqueline Bernard

There are errors in the author affiliations. The affiliations should appear as shown here: Garrick D. Talmage1, Oscar J. M. Coppes2, Adil Javed3, Jacqueline Bernard4

1 Department of Otolaryngology, University of Colorado, Aurora, Colorado, United States of America, 2 Department of Anesthesia, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 3 Department of Neurology, The University of Chicago, Chicago, Illinois, United States of America, 4 Department of Neurology, Oregon Health Science University, Portland, Oregon, United States of America.

Reference

  1. 1. Talmage GD, Coppes OJM, Javed A, Bernard J (2017) Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS ONE 12(4): e0173299. https://doi.org/10.1371/journal.pone.0173299 pmid:28426702

Citation: Talmage GD, Coppes OJM, Javed A, Bernard J (2017) Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS ONE 12(5): e0178338. https://doi.org/10.1371/journal.pone.0178338

Published: May 18, 2017

Copyright: © 2017 Talmage et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.